$1.2 B

CORT Mkt cap, 10-Jun-2019
Corcept Therapeutics Net income (Q2, 2019)20.2 M
Corcept Therapeutics EBIT (Q2, 2019)24.6 M
Corcept Therapeutics Cash, 30-Jun-201958.1 M

Corcept Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

10.4m26.6m50.3m81.3m

Revenue growth, %

156%89%62%

Cost of goods sold

143.0k882.0k1.4m2.1m3.6m5.2m

Gross profit

10.2m25.7m48.9m79.3m

Gross profit Margin, %

99%97%97%97%

R&D expense

15.4m23.8m40.4m75.2m

General and administrative expense

31.2m34.9m36.9m45.2m62.4m81.3m

Operating expense total

31.2m34.9m53.7m69.1m106.3m161.8m

EBIT

(41.5m)(27.6m)(3.4m)10.2m52.9m89.5m

EBIT margin, %

(401%)(104%)(7%)13%

Interest expense

4.5m3.8m2.0m

Interest income

2.7m

Pre tax profit

52.8m92.2m

Income tax expense

76.3m16.7m

Net Income

(46.0m)(31.4m)(6.4m)8.1m129.1m75.4m

Quarterly

USDQ3, 2013Q3, 2014Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

2.6m7.3m

Cost of goods sold

40.0k235.0k646.0k775.0m976.0k1.2m1.2m1.3m1.2m1.4m

Gross profit

2.6m7.0m

Gross profit Margin, %

98%97%

R&D expense

5.2m3.0m7.2m7.9b11.7m17.1m20.5m18.9m20.2m21.7m

General and administrative expense

7.2m9.1m15.0m14.1b16.5m18.4m20.0m21.3m24.4m24.6m

Operating expense total

12.4m12.4m22.9m22.8b29.1m36.7m41.7m41.5m45.9m47.6m

EBIT

(9.7m)(5.1m)4.7m12.8b13.6m21.0m20.6m23.0m19.0m24.6m

EBIT margin, %

(370%)(70%)

Interest income

86.0k294.0k562.0k759.0k1.1m1.2m

Pre tax profit

4.5m12.7b13.7m21.3m21.2m23.7m20.1m25.8m

Income tax expense

(127.0k)(50.0m)48.0k(3.8m)(3.0m)(6.0m)(1.8m)(5.6m)

Net Income

4.4m12.6b13.8m17.5m18.2m17.7m18.3m20.2m

Corcept Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

54.9m24.2m40.4m51.5m31.1m41.6m

Accounts Receivable

Inventories

1.1m1.4m1.7m2.3m4.6m4.7m

Current Assets

58.3m30.2m49.0m65.7m124.2m236.8m

PP&E

203.0k236.0k98.0k205.0k518.0k655.0k

Total Assets

63.1m34.6m51.9m68.8m220.5m311.7m

Accounts Payable

2.4m1.9m1.3m2.3m8.6m8.3m

Short-term debt

Current Liabilities

12.7m13.6m20.9m27.4m29.6m35.6m

Long-term debt

Total Debt

Total Liabilities

35.8m

Additional Paid-in Capital

313.5m320.5m348.8m363.5m384.1m417.2m

Retained Earnings

(292.6m)(324.0m)(330.4m)(322.3m)(193.1m)(117.7m)

Total Equity

21.0m(3.4m)18.5m41.4m191.0m275.9m

Financial Leverage

3 x-10.2 x2.8 x1.7 x1.2 x1.1 x

Corcept Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(46.0m)(31.4m)(6.4m)8.1m129.1m75.4m

Accounts Receivable

Inventories

(883.0k)(531.0k)815.0k(682.0k)(2.3m)(7.8m)

Accounts Payable

(1.4m)(495.0k)(561.0k)965.0k6.3m(389.0k)

Cash From Operating Activities

(37.1m)(27.4m)3.1m18.4m60.9m115.7m

Purchases of PP&E

(127.0k)(174.0k)(17.0k)(194.0k)(419.0k)(298.0k)

Cash From Investing Activities

(127.0k)(17.0k)(194.0k)(73.5m)(90.8m)

Cash From Financing Activities

(970.0k)(3.1m)13.1m(7.1m)(8.0m)(14.3m)

Income Taxes Paid

377.0k1.4m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

30.8m17.5m35.7m53.4m18.3m38.5m

Accounts Receivable

1.0m

Inventories

1.0m1.1m1.1m1.1m1.3m1.5m1.6m1.9m2.1m2.3m2.9m(344.0k)590.0k(2.1m)(4.3m)910.0k(1.5m)

Accounts Payable

2.3m3.7m2.6m2.0m1.0m2.4m1.7m2.1m2.1m4.3m4.3m3.9m(759.0k)(2.2m)5.3m953.0k(1.3m)

Cash From Operating Activities

36.1m34.4m49.6m94.1m23.7m49.2m

Purchases of PP&E

(390.0k)(77.0k)(140.0k)(185.0k)(257.0k)(667.0k)

Cash From Investing Activities

(46.0m)(34.3m)(55.5m)(89.0m)(367.0k)(1.5m)

Cash From Financing Activities

(10.5m)1.9m6.0m(2.3m)(15.3m)(31.2m)

Corcept Therapeutics Ratios

USDY, 2019

Financial Leverage

1.1 x

Corcept Therapeutics Employee Rating

3.87 votes
Culture & Values
4.1
Work/Life Balance
3.6
Senior Management
3.4
Salary & Benefits
4.3
Career Opportunities
2.9
Source